Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 7Recruiting 6Active not recruiting 5Terminated 4Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 40Carcinoma, Non-Small-Cell Lung 35Carcinoma, Renal Cell 26Neoplasm Metastasis 19Lung Neoplasms 18Carcinoma, Hepatocellular 15Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Neoplasms 9Carcinoma, Transitional Cell 9Multiple Myeloma 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Head and Neck Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Hodgkin Disease 6Advanced Cancer 6Myelodysplastic Syndromes 5Hematologic Neoplasms 5Brain Neoplasms 5Skin Neoplasms 4Recurrence 4Lymphoma 4Kidney Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Uveal Melanoma 3

Interventions

Cyclophosphamide 12aldesleukin 9fludarabine 8fludarabine phosphate 7pembrolizumab 6Ipilimumab 5Interleukin-2 5Nivolumab 4dabrafenib 2Vemurafenib 2Biopsy 2Aminolevulinic Acid 2varlilumab 1trametinib 1tilsotolimod 1spartalizumab 1sotigalimab 1sonidegib 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1glembatumumab vedotin 1eprenetapopt 1epacadostat 1encorafenib 1cemiplimab 1cabozantinib 1binimetinib 1bempegaldesleukin 1abobotulinumtoxinA 1X-Rays 1Tranexamic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Skin Neoplasms × Nivolumab × Clear all
NCT05926960 2026-03-09

PORTSIDE

Pfizer

Phase 2 Terminated
38 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT04410445 2023-04-21

PIVOT-12

Nektar Therapeutics

Phase 3 Terminated
765 enrolled 13 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT04311710 2023-02-24

CheckMate 76U

Bristol-Myers Squibb

Phase 1 Terminated
21 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Skin Neoplasms

NCT02302339 2019-09-06

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Celldex Therapeutics

Phase 2 Terminated
132 enrolled 16 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡